FINHUB Insights

VRTX · Q4 FY25 · Oct 1 – Dec 31, 2025

Vertex Pharmaceuticals Q4 FY25: where the revenue came from and where it went

Vertex Pharmaceuticals Q4 FY25: revenue $3.2B (+10% year over year). Net profit $1.2B. Largest cohort TRIKAFTAKAFTRIO $2.6B. The whole income statement as a sankey diagram from the SEC filing.

Period
Oct 1 – Dec 31, 2025
Reported
Feb 13, 2026 10-K
Sankey diagram of Vertex Pharmaceuticals's income statement for Q4 FY25: revenue of $3.2 billion splits into segments and flows out into costs, taxes and net profit.

Tap the diagram to enlarge · figures in billions of dollars

Revenue$3.2B +10% year over year
Gross profit$2.7B 85% margin
Operating profit$1.2B 38% margin
Net profit$1.2B 37% margin

The numbers

All figures in billions of U.S. dollars, for Q4 FY25 (period ends Dec 31, 2025).
ItemValueShare of revenueYear over year
Revenue 3.2 100% +10%
TRIKAFTAKAFTRIO 2.6 81% −5%
ALYFTREK 0.4 12%
Manufactured Product Other 0.2 6% +24%
Cost of revenue−0.516%
Gross profit2.785% margin+0pp
SG&A−0.515%+2pp
Other−132%+0pp
Operating profit1.238% margin+3pp
Tax−0.1
Net profit1.237%+6pp
Filing on EDGAR More quarters of VRTX

Source of the numbers: structured XBRL data from the filing (10-K). The diagram is generated automatically and checked against EDGAR before release. The fourth quarter has no column of its own in an annual report, so it is the full year minus the first nine months. How we calculate it → About and methodology.

Older quarters